Retrouvez tous les articles publiés par l'IFCT chaque année.




Role of the YAP-1 Transcriptional Target cIAP2 in the Differential Susceptibility to Chemotherapy of Non-Small-Cell Lung Cancer (NSCLC) Patients with Tumor RASSF1A Gene Methylation from the Phase 3 IFCT-0002 Trial.
Dubois F, Keller M, Hoflack J, Maille E, Antoine M, Westeel V, Bergot E, Quoix E, Lavolé A, Bigay-Game L, Pujol JL, Langlais A, Morin F, Zalcman G, Levallet G.
Cancers (Basel). 2019 Nov 21 

Brief report : High MET overexpression does not predict the presence of MET exon 14 splice mutations in NSCLC : results from the IFCT Predict.amm study.
Baldacci S, Figeac M, Antoine M, Descarpentries C, Kherrouche Z, Jamme P, Copin MC, Tulasne D, Nanni I, Beau-Faller M, Melaabi S, Levallet G, Quoix E, Moro-Sibilot D, Friard S, Missy P, Barlesi F, Cadranel J, Cortot AB.
J Thorac Oncol. 2019 Oct 9

Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial.
Moro-Sibilot D, Cozic N, Pérol M, Mazières J, Otto J, Souquet PJ, Bahleda R, Wislez M, Zalcman G, De Guibert S, Barlési F, Mennecier B, Monnet I, Sabatier R, Bota S, Dubos C, Verriele V, Haddad V, Ferretti G, Cortot A, De Fraipont F, Jimenez M, Hoog-Labouret N, Vassal G.
Ann Oncol. 2019 Oct 4

Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.
Brosseau S, Danel C, Scherpereel A, Mazières J, Lantuejoul S, Margery J, Greillier L, Audigier-Valette C, Gounant V, Antoine M, Moro-Sibilot D, Rouquette I, Molinier O, Corre R, Monnet I, Langlais A, Morin F, Bergot E, Zalcman G, Levallet G.
Clin Lung Cancer. 2019 Sep 20

Clinical outcomes of non-small-cell lung cancer patients with BRAF mutations: results from the French Cooperative Thoracic Intergroup biomarkers France study.
Couraud S, Barlesi F, Fontaine-Deraluelle C, Debieuvre D, Merlio JP, Moreau L, Beau-Faller M, Veillon R, Mosser J, Al Freijat F, Bringuier PP, Léna H, Ouafik L, Westeel V, Morel A, Audigier-Valette C, Missy P, Langlais A, Morin F, Souquet PJ, Planchard D; Biomarkers France Contributors.
Eur J Cancer. 2019 Jun 7;116:86-97. 

ST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial
Maille E, Brosseau S, Hanoux V, Creveuil C, Danel C, Bergot E, Scherpereel A, Mazières J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Langlais A, Morin F, Levallet G, Zalcman G.
Br J Cancer. 2019 Feb 11. 

A Randomized Non-Comparative Phase 2 Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients with Small Cell Lung Cancer: Results from the IFCT 1603 Trial.
Pujol JL, Greillier L, Audigier-Valette C, Moro-Sibilot D, Uwer L, Hureaux J, Guisier F, Carmier D, Madelaine J, Otto J, Gounant V, Merle P, Mourlanette P, Molinier O, Renault A, Rabeau A, Antoine M, Denis MG, Bommart S, Langlais A, Morin F, Souquet PJ.
J Thorac Oncol. 2019 Jan 18. 
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial
Scherpereel A, Mazieres J, Greillier L, Lantuejoul S, Dô P, Bylicki O, Monnet I, Corre R, Audigier-Valette C, Locatelli-Sanchez M, Molinier O, Guisier F, Urban T, Ligeza-Poisson C, Planchard D, Amour E, Morin F, Moro-Sibilot D, Zalcman G, on behalf of the French Cooperative Thoracic Intergroup
Lancet Oncology. 2019 Jan 16.

Clinical Relevance of EGFR- or KRAS-mutated Subclones in Patients With Advanced Non-small-cell Lung Cancer Receiving Erlotinib in a French Prospective Cohort (IFCT ERMETIC2 Cohort - Part 2)
Beau-Faller M, Texier M, Blons H, Richard N, Escande F, Melaabi S, Lizard S, De Fraipont F, Longchampt E, Morin F, Zalcman G, Pignon JP, Cadranel J.
Clin Lung Cancer. 2018 Dec 19. 

[IoNESCO trial: Immune neoajuvant therapy in early stage non-small cell lung cancer].
Mignard X, Antoine M, Moro-Sibilot D, Dayen C, Mennecier B, Gervais R, Amour E, Milleron B, Morin F, Zalcman G, Wislez M.
Rev Mal Respir. 2018 Sep 19. 

Systemic therapy in advanced thymic epithelial tumors: Insights from the RYTHMIC prospective cohort.
Merveilleux du Vignaux C, Dansin E, Mhanna L, Greillier L, Pichon E, Kerjouan M, Clement-Duchene C, Mennecier B, Westeel V, Robert M, Quantin X, Zalcman G, Thiberville L, Lena H, Molina T, Calcagno F, Fournel P, Mazieres J, Besse B, Girard N.
J Thorac Oncol. 2018 Aug 20. 

Cost-effectiveness of KRAS, EGFR and ALK testing for decision making in advanced nonsmall cell lung carcinoma: the French IFCT-PREDICT.amm study.
Loubière S, Drezet A, Beau-Faller M, Moro-Sibilot D, Friard S, Wislez M, Blons H, Daniel C, Westeel V, Madroszyk A, Léna H, Merle P, Mazières J, Zalcman G, Lacave R, Antoine M, Morin F, Missy P, Barlesi F, Auquier P, Cadranel J; French Cooperative Thoracic Intergroup (IFCT).
Eur Respir J. 2018 Mar 15;51(3).

Phase II study assessing the benefit of cisplatin re-introduction (stop-and-go strategy) in patients with advanced non-squamous non-small cell lung cancer: the IFCT-1102 BUCiL study (a Better Use of Cisplatin in Lung cancer)
Bennouna J, Barlesi F, Do P, Dumont P, Cadranel J, Debieuvre D, Hilgers W, Molinier O, Quoix E, Raimbourg J, Langlais A, Morin F, Souquet P.J
ESMO Open. 2018 Jul 23;3(5):e000394.
Open access

Structuration de la cancérologie thoracique française dans ces 20 dernières années
Milleron B.
Rev Mal Respir. 2017 Nov12; 34(9)

Association between lung cancer somatic mutations and occupational exposure in never-smokers.
Paris C, Do P, Mastroianni B, Dixmier A, Dumont P, Pichon E, Chouaid C, Coudert B, Foucher P, Fraboulet S, Locatelli-Sanchez M, Baize N, Dansin E, Moreau L, Vincent M, Missy P, Morin F, Moro-Sibilot D, Couraud S; BioCAST/IFCT-1002 study investigators; to the BioCAST/IFCT- 1002 study.
Eur Respir J. 2017 Oct 26;50(4).

Clinical and molecular characteristics of non-small cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program.
Leduc C, Merlio JP, Besse B, Blons H, Debieuvre D, Bringuier PP, Monnet I, Rouquette I, Fraboulet-Moreau S, Lemoine A, Pouessel D, Mosser J, Vaylet F, Langlais A, Missy P, Morin F, Moro-Sibilot D, Cadranel J, Barlesi F, Beau-Faller M; French Cooperative Thoracic Intergroup (IFCT).
Ann Oncol. 2017 Jul 28.

Current knowledge on perioperative treatments of non-small cell lung carcinomas
Brosseau S, Naltet C, Nguenang M, Gounant V, Mordant P, Milleron B, Castier Y, Zalcman G.
Rev Mal Respir. 2017 Jun;34(6):618-634.

EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice
Tomasini P, Brosseau S, Mazières J, Merlio J.P, Beau-Faller M, Mosser J, Wislez MOuafik L, Besse B, Rouquette I, Debieuvre D, Escande F, Westeel V, Audigier-Valette C, Missy P, Langlais A, Morin F, Moro-Sibilot D, Zalcman G, Barlesi F

Safeguarding the future of independent, academic clinical cancer research in Europe for the benefit of patients.
Negrouk A, Lacombe D, Cardoso F, Morin F, Carrasco E, Maurel J, Maibach R, Aranda E, Marais R, Stahel R.
ESMO open. 2017 Aug 3.

Clinical research activity of the French cancer cooperative network: Overview and perspectives.
Dubois C, Morin F, Moro-Sibilot D, Langlais A, Seitz JF, Girault C, Salles G, Haioun C, Deschaseaux P, Casassus P, Mathiot C, Pujade-Lauraine É, Votan B, Louvet C, Delpeut C, Bardet É, Vintonenko N, Hoang Xuan K, Vo M, Michon J, Milleron B.
Bull Cancer. 2017 Jul 5.

Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK) : a French nationwide cohort retrospective study.
Duruisseaux M, Besse B, Cadranel J, Pérol M, Mennecier B, Bigay-Game L, Descourt R, Dansin E, Audigier-Valette C, Moreau L, Hureaux J, Veillon R, Otto J, Madroszyk-Flandin A, Cortot A, Guichard F, Boudou-Rouquette P, Langlais A, Missy P, Morin F, Moro-Sibilot D.
. 2017 Mar 28.

Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial.
Besse B, Mazières J, Ribassin-Majed L, Barlesi F, Bennouna J, Gervais R, Moreau L, Berard H, Debieuvre D, Molinier O, Moro-Sibilot D, Souquet PJ, Jacquot S, Petit L, Lena H, Pignon JP, Lacas B, Morin F, Milleron B, Zalcman G, Soria JC; Intergroupe Francophone de Cancérologie Thoracique (IFCT).
Ann Oncol
. 2017 Feb 23.

Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France.
Guibert N, Barlesi F, Descourt R, Léna H, Besse B, Beau-Faller M, Mosser J, Pichon E, Merlio JP, Ouafik L, Guichard F, Mastroianni B, Moreau L, Wdowik A, Sabourin JC, Lemoine A, Missy P, Langlais A, Moro-Sibilot D, Mazieres J.
J Thorac Oncol. 2017 Feb 9.

MSH2/BRCA1 expression as a DNA-repair signature predicting survival in early-stage lung cancer patients from the IFCT-0002 Phase 3 Trial.
Levallet G, Dubois F, Fouret P, Antoine M, Brosseau S, Bergot E, Beau-Faller M, Gounant V, Brambilla E, Debieuvre D, Molinier O, Galateau-Sallé F, Mazieres J, Quoix E, Pujol JL, Moro-Sibilot D, Langlais A, Morin F, Westeel V, Zalcman G.
Oncotarget. 2016 Dec 19.

Lung Cancer Screening with Chest Computed Tomography in People Living with HIV. A Review by the Multidisciplinary CANCERVIH Working Group
Makinson A, Le Moing V, Reynes J, Ferry T, Lavole A, Poizot-Martin I, Pujol JL, Spano JP, Milleron B.
J Thorac Oncol. 2016 Jul 20.

Sunitinib in patients with advanced thymic malignancies: Cohort from the French RYTHMIC network.
Remon J, Girard N, Mazieres J, Dansin E, Pichon E, Grellier L, Dubos C, Lindsay CR, Besse B.
Lung Cancer. 2016 Jul;97:99-104. Epub 2016 May 3

Health-related quality of life in elderly patients with advanced non-small cell lung cancer comparing carboplatin and weekly paclitaxel doublet chemotherapy with monotherapy.
Fiteni F, Anota A, Bonnetain F, Oster JP, Pichon E, Wislez M, Dauba J, Debieuvre D, Souquet PJ, Bigay-Game L, Molinier O, Dansin E, Poudenx M, Milleron B, Morin F, Zalcman G, Quoix E, Westeel V.
Eur Respir J. 2016 Jun 23.

Sensitivity to chemotherapy/tyrosine kinase inhibitors of mucinous lepidic adenocarcinoma should be tested in a phase III trial?
Cadranel J, Wislez M, Langlais A, Morin F, Zalcman G.
Eur Respir J. 2016 Jun;47(6):1890-1.

Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).
Barlesi F, Mazieres J, Merlio JP, Debieuvre D, Mosser J, Lena H, Ouafik L, Besse B, Rouquette I, Westeel V, Escande F, Monnet I, Lemoine A, Veillon R, Blons H, Audigier-Valette C, Bringuier PP, Lamy R, Beau-Faller M, Pujol JL, Sabourin JC, Penault-Llorca F, Denis MG, Lantuejoul S, Morin F, Tran Q, Missy P, Langlais A, Milleron B, Cadranel J, Soria JC, Zalcman G; Biomarkers France contributors.
Lancet. 2016 Jan 14.

Induction or consolidation chemotherapy for unresectable stage III non-small-cell lung cancer patients treated with concurrent chemoradiation: a randomised phase II trial GFPC - IFCT 02-01.
Fournel P, Vergnenégre A, Robinet G, Léna H, Gervais R, Le Caer H, Souquet PJ, Chavaillon JM, Bozonnat MC, Daurès JP, Chouaid C, Martel-Lafay I; GFPC and IFCT team.
Eur J Cancer. 2016 Jan; 52 : 181-7

Prognostic value of health-related quality of life for overall survival in elderly non-small-cell lung cancer patients.
Fiteni F, Vernerey D, Bonnetain F, Vaylet F, Sennélart H, Trédaniel J, Moro-Sibilot D, Herman D, Laizé H, Masson P, Derollez M, Clément-Duchêne C, Milleron B, Morin F, Zalcman G, Quoix E, Westeel V.
Eur J Cancer. 2016 Jan; 52 : 120-8

Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Rivière F, Janicot H, Gervais R, Locher C, Milleron B, Tran Q, Lebitasy MP, Morin F, Creveuil C, Parienti JJ, Scherpereel A; French Cooperative Thoracic Intergroup (IFCT).
Lancet. 2015 Dec 21.

[Pathological complete response: A predictive survival factor after neoadjuvant chemotherapy in lung cancer].
Milleron B, Westeel V, Gounant V, Wislez M, Quoix E.
Bull Cancer. 2015 Dec 9.

Reply to the letter to the editor 'Prevalence of rare EGFR mutations in non-small cell lung cancer: a multicenter study on 3856 Polish Caucasian patients' by Krawczyk et al.
Beau-Faller M, Cadranel J.
Ann Oncol. 2015 Dec 9.

Erlotinib versus carboplatin and paclitaxel in advanced lepidic adenocarcinoma: IFCT-0504.
Cadranel J, Gervais R, Merle P, Moro-Sibilot D, Westeel V, Bigay-Game L, Quoix E, Friard S, Barlesi F, Lethrosne C, Moreau L, Monnet I, Salaun M, Oliviero G, Souquet PJ, Antoine M, Langlais A, Morin F, Wislez M, Zalcman G; Intergroupe Francophone de Cancérologie Thoracique (IFCT).
Eur Respir J. 2015 Nov;46(5):1440-50.

Reply to the letter to the editor 'Flaws in the trial design of IFCT-0802' by Gyawali et al.
Pujol JL, Morin F, Zalcman G; IFCT.
Ann Oncol. 2015 Aug 7.

Non-small cell lung cancer recurrence following surgery and perioperative chemotherapy: Comparison of two chemotherapy regimens (IFCT-0702: A randomized phase 3 final results study).
Moro-Sibilot D, Audigier-Valette C, Merle P, Quoix E, Souquet PJ, Barlesi F, Chouaid C, Molinier O, Bennouna J, Lavolé A, Mazières J, Toffart AC, Langlais A, Morin F, Zalcman G.
Lung Cancer. 2015 Aug;89(2):139-45.

Randomized Phase II-III Study of Bevacizumab in Combination with Chemotherapy in Previously Untreated Extensive Small-Cell Lung Cancer: Results from the IFCT-0802 Trial.
Pujol JL, Lavole A, Quoix E, Molinier O, Souquet PJ, Barlesi F, Le Caer H, Moro-Sibilot D, Fournel P, Oster JP, Chatellain P, Barre P, Jeannin G, Mourlanette P, Derollez M, Herman D, Renault A, Dayen C, Lamy PJ, Langlais A, Morin F, Zalcman G; French Cooperative Thoracic Intergroup (IFCT).
Ann Oncol. 2015 May;26(5):908-14.

No impact of passive smoke on the somatic profile of lung cancers in never-smokers.
Couraud S, Debieuvre D, Moreau L, Dumont P, Margery J, Quoix E, Duvert B, Cellerin L, Baize N, Taviot B, Coudurier M, Cadranel J, Missy P, Morin F, Mornex JF, Zalcman G, Souquet PJ;
Eur Respir J. 2015 May;45(5):1415-25.

Similar survival rates with first-line gefitinib, gemcitabine, or docetaxel in a randomized phase II trial in elderly patients with advanced non-small cell lung cancer and a poor performance status (IFCT-0301).
Des Guetz G, Landre T, Westeel V, Milleron B, Vaylet F, Urban T, Barlesi F, Souquet PJ, Debieuvre D, Braun D, Fraboulet G, Monnet I, Uzzan B, Molinier O, Morin F, Moro-Sibilot D, Morère JF.
J Geriatr Oncol. 2015 May;6(3):233-40.

BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokers.
Couraud S, Souquet PJ, Paris C, Dô P, Doubre H, Pichon E, Dixmier A, Monnet I, Etienne-Mastroianni B, Vincent M, Trédaniel J, Perrichon M, Foucher P, Coudert B, Moro-Sibilot D, Dansin E, Labonne S, Missy P, Morin F, Blanché H, Zalcman G; on behalf of The French Cooperative Intergroup IFCT.
Eur Respir J. 2015 Feb 5.

Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study.
Borget I, Pérol M, Pérol D, Lavolé A, Greillier L, Dô P, Westeel V, Crequit J, Léna H, Monnet I, Le Caer H, Fournel P, Falchero L, Poudenx M, Vaylet F, Chabaud S, Vergnenegre A, Zalcman G, Chouaïd C.
BMC Cancer. 2014 Dec 15;14(1):953.

RhoB Determines Tumor Aggressiveness in a Murine EGFRL858R-Induced Adenocarcinoma Model and Is a Potential Prognostic Biomarker for Lepidic Lung Cancer.
Calvayrac O, Pradines A, Raymond-Letron I, Rouquette I, Bousquet E, Lauwers-Cances V, Filleron T, Cadranel J, Beau-Faller M, Casanova A, Milia J, Favre G, Mazières J.
Clin Cancer Res. 2014 Oct 15.

Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-of-concept study from BioCAST/IFCT-1002.
Couraud S, Vaca-Paniagua F, Villar S, Oliver J, Schuster T, Blanché H, Girard, N, Trédaniel J, Guilleminault L, Gervais R, Prim N, Vincent M, Margery J, Larivé S, Foucher P, Duvert B, Vallee M, Le Calvez-Kelm F, McKay J, Missy P, Morin F, Zalcman G, Olivier M, Souquet PJ; BioCAST/IFCT-1002 investigators.
Clin Cancer Res. 2014 Sep 1;20(17):4613-24.

Estimating overdiagnosis in lung cancer screening.
Couraud S, Greillier L, Milleron B; IFCT Lung Cancer Screening Group.
JAMA Intern Med. 2014 Jul;174(7):1197.

Customized Adjuvant Phase II Trial in Patients With Non-Small-Cell Lung Cancer: IFCT-0801 TASTE.
Wislez M, Barlesi F, Besse B, Mazières J, Merle P, Cadranel J, Audigier-Valette C, Moro-Sibilot D, Gautier-Felizot L, Goupil F, Renault A, Quoix E, Souquet PJ, Madroszyck A, Corre R, Pérol D, Morin F, Zalcman G, Soria JC.
J Clin Oncol. 2014 Mar 17.

[Lung cancer and HIV infection].
Lavolé A, Toper C, Belmont L, Ruppert AM, Wislez M, Cadranel J.
Rev Mal Respir. 2014 Feb;31(2):133-141.

[Individual lung cancer screening in practice. Perspectives on the propositions from the multidisciplinary group of the Intergroupe francophone de cancérologie thoracique, the Société d'imagerie thoracique and the Groupe d'oncologie de langue française].
Girard N, Gounant V, Mennecier B, Greillier L, Cortot AB, Couraud S, Besse B, Brouchet L, Castelnau O, Ferretti GR, Frappé P, Khalil A, Lefebure P, Laurent F, Liebart S, Margery J, Molinier O, Quoix E, Revel MP, Stach B, Souquet PJ, Thomas P, Trédaniel J, Lemarié E, Zalcman G, Barlési F, Milleron B; groupe de travail multidisciplinaire de l’Intergroupe francophone de cancérologie thoracique, de la Société d’imagerie thoracique et du Groupe d’oncologie de langue française.
Rev Mal Respir. 2014 Jan;31(1):91-103.

Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network.
Beau-Faller M, Prim N, Ruppert AM, Nanni-Metéllus I, Lacave R, Lacroix L, Escande F, Lizard S, Pretet JL, Rouquette I, de Crémoux P, Solassol J, de Fraipont F, Bièche I, Cayre A, Favre-Guillevin E, Tomasini P, Wislez M, Besse B, Legrain M, Voegeli AC, Baudrin L, Morin F, Zalcman G, Quoix E, Blons H, Cadranel J.
Ann Oncol. 2014 Jan;25(1):126-31

A Multicenter Blinded Study Evaluating EGFR and KRAS Mutation Testing Methods in the Clinical Non-Small Cell Lung Cancer Setting-IFCT/ERMETIC2 Project Part 1: Comparison of Testing Methods in 20 French Molecular Genetic National Cancer Institute Platforms.
Beau-Faller M, Blons H, Domerg C, Gajda D, Richard N, Escande F, Solassol J, Denis MG, Cayre A, Nanni-Metellus I, Olschwang S, Lizard S, Piard F, Pretet JL, de Fraipont F, Bièche I, de Cremoux P, Rouquette I, Bringuier PP, Mosser J, Legrain M, Voegeli AC, Saulnier P, Morin F, Pignon JP, Zalcman G, Cadranel J.
J Mol Diagn. 2014 Jan;16(1):45-55

Second-line therapy in elderly patients with advanced non-small cell lung carcinoma: analysis of the IFCT-0501 Phase III study comparing single-agent therapy to carboplatin-based doublet therapy with fixed second-line erlotinib therapy.
Quoix E, Westeel V, Moreau L, Pichon E, Lavolé A, Dauba J, Debieuvre D, Souquet PJ, Bigay-Game L, Dansin E, Poudenx M, Molinier O, Vaylet F, Moro-Sibilot D, Herman D, Sennelart H, Tredaniel J, Mennecier B, Morin F, Baudrin L, Milleron B, Zalcman G; on behalf of Intergroupe Francophone de CancérologieThoracique.
Eur Respir J. 2014 Jan;43(1):240-9.

Reply to letter EJC-D-13-01186.
Westeel V, Quoix E, Zalcman G, Milleron B.
Eur J Cancer. 2013 Dec 10.

The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism.
Jeannot V, Busser B, Brambilla E, Wislez M, Robin B, Cadranel J, Coll JL, Hurbin A.
Int J Cancer. 2013 Nov 8

Lung cancer in never smokers: A French national cohort (BioCAST/IFCT-1002).
Couraud S, Labonne S, Missy P, Morin F, Tran Q, Deroy A, Milleron B, Blanché H, Zalcman G, Souquet PJ; les membres du Groupe de travail « non-fumeurs de l’IFCT ».
Rev Mal Respir. 2013 Sep;30(7):576-83.

A randomised trial comparing preoperative to perioperative chemotherapy in early-stage non-small-cell lung cancer (IFCT 0002 trial).
Westeel V, Quoix E, Puyraveau M, Lavolé A, Braun D, Laporte S, Bigay-Game L, Pujol JL, Ozenne G, Rivière A, Douillard JY, Lebeau B, Debieuvre D, Poudenx M, David P, Molinier O, Zalcman G, Lemarié E, Morin F, Depierre A, Milleron B; IFCT (Intergroupe Francophone de Cancérologie Thoracique).
Eur J Cancer. 2013 Aug;49(12):2654-64

Efficacy of Pemetrexed as Second-Line Therapy in Advanced NSCLC after Either Treatment-Free Interval or Maintenance Therapy with Gemcitabine or Erlotinib in IFCT-GFPC 05-02 Phase III Study.
Bylicki O, Ferlay C, Chouaid C, Lavolé A, Barlési F, Dubos C, Westeel V, Créquit J, Corre R, Vergnenègre A, Monnet I, Le Caer H, Fournel P, Vaylet F, Falchero L, Poudenx M, Linard P, Pérol D, Zalcman G, Pérol M.
J Thorac Oncol. 2013 Jul;8(7):906-914

From the NLST randomized trial to the clinic: How should we implement individual lung cancer screening in clinical practice?
Couraud S, Barlesi F, Lemarié E, Zalcman G, Milleron B; pour le groupe de travail IFCT/GOLF sur le dépistage du cancer broncho-pulmonaire.
Rev Mal Respir. 2013 Jan;30(1):15-7

From randomized trials to the clinic: is it time to implement individual lung-cancer screening in clinical practice? A multidisciplinary statement from French experts on behalf of the french intergroup (IFCT) and the groupe d’Oncologie de langue française (GOLF).

S. Couraud, A. Cortot, L. Greillier, V. Gounant, B. Mennecier, N. Girard, B. Besse, L. Brouchet, O. Castelnau, P. Frappé, G. Ferretti, L. Guittet, A. Khalil, P. Lefebure, F. Laurent, S. Liebart, O. Molinier, E. Quoix, M-P. Revel, B. Stach, P-J. Souquet, P. Thomas, J. Trédaniel, E. Lemarié, G. Zalcman, F. Barlesi, B. Milleron on behalf of the French lung cancer screening statement taskforce.
Annals of  Oncology first published online November 7, 2012
Article en libre accès

Ann Oncol. 2013 Mar;24(3):586-97

Impact of Systematic EGFR and KRAS Mutation Evaluation on Progression-Free Survival and Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Treated by Erlotinib in a French Prospective Cohort (ERMETIC Project-Part 2).
Cadranel J, Mauguen A, Faller M, Zalcman G, Buisine MP, Westeel V, Longchampt E, Wislez M, Coudert B, Daniel C, Chetaille B, Michiels S, Blons H, Solassol J, De Fraipont F, Foucher P, Urban T, Lacroix L, Poulot V, Quoix E, Antoine M, Danton G, Morin F, Chouaid C, Pignon JP.
J Thorac Oncol. 2012 Oct;7(10):1490-1502

Therapeutic options in older patients with metastatic non-small cell lung cancer.
Quoix E.
Ther Adv Med Oncol. 2012 Sep;4(5):247-54

Randomized, Phase III Study (IFCT-GFPC 0502) of Gemcitabine or Erlotinib Maintenance Therapy Versus Observation, With Predefined Second-Line Treatment, After Cisplatin-Gemcitabine Induction Chemotherapy in Advanced Non-Small-Cell Lung Cancer.
Pérol M, Chouaid C, Pérol D, Barlési F, Gervais R, Westeel V, Crequit J, Léna H, Vergnenègre A, Zalcman G, Monnet I, Le Caer H, Fournel P, Falchero L, Poudenx M, Vaylet F, Ségura-Ferlay C, Devouassoux-Shisheboran M, Taron M, Milleron B.
Journal of Clinical Oncology 2012 Sep 4.

Chemotherapy Effectiveness After First-Line Gefitinib Treatment for Advanced Lepidic Predominant Adenocarcinoma (Formerly Advanced Bronchioloalveolar Carcinoma): Exploratory Analysis of the IFCT-0401 Trial.
Duruisseaux M, Baudrin L, Quoix E, Wislez M, Moro-Sibilot D, Coëtmeur D, Monnet I, Mourlanette P, Morère JF, Soria JC, Westeel V, Morin F, Cadranel J.
Journal of Thoracic Oncology 2012 Sep;7(9):1423-1431.

Pathologic complete response to preoperative chemotherapy predicts cure in early-stage non-small-cell lung cancer: combined analysis of two IFCT randomized trials.
Mouillet G, Monnet E, Milleron B, Puyraveau M, Quoix E, David P, Ducoloné A, Molinier O, Zalcman G, Depierre A, Westeel V; Intergroupe Francophone de Cancérologie Thoracique (IFCT).
Jounal of Thoracic Oncology 2012 May;7(5):841-9.

Professional Exposure to Goats Increases the Risk of Pneumonic-Type Lung Adenocarcinoma: Results of the IFCT-0504-Epidemio Study.
Lutringer-Magnin D, Girard N, Cadranel J, Leroux C, Quoix E, Cottin V, Signore CD, Lebitasy MP, Cordier G, Vanhems P, Mornex JF.
PLoS One. 2012; 7 : e37889.

An Apoptosis Methylation Prognostic Signature for Early Lung Cancer in the IFCT-0002 Trial.
De Fraipont F, Levallet G, Creveuil C, Bergot E, Beau-Faller M, Mounawar M, Richard N, Antoine M, Rouquette I, Favrot MC, Debieuvre D, Braun D, Westeel V, Quoix E, Brambilla E, Hainaut P, Moro-Sibilot D, Morin F, Milleron B, Zalcman G; on behalf of the Intergroupe Francophone de Cancérologie Thoracique (IFCT).
Clinical Cancer Research 2012 ; 18 : 2976-2986.

Pathologic Complete Response to Preoperative Chemotherapy Predicts Cure in Early-Stage Non–Small-Cell Lung Cancer. Combined Analysis of Two IFCT Randomized Trials.
Guillaume Mouillet, Elisabeth Monnet, Bernard Milleron, Marc Puyraveau, Elisabeth Quoix,Philippe David, Alain Ducoloné, Olivier Molinier, Gérard Zalcman, Alain Depierre, Virginie Westeel, on behalf of the Intergroupe Francophone de Cancérologie Thoracique (IFCT).
Journal of Thoracic Oncology  2012;  7 : 841-849

High TUBB3 Expression, an Independent Prognostic Marker in Patients with Early Non-Small Cell Lung Cancer Treated by Preoperative Chemotherapy, Is Regulated by K-Ras Signaling Pathway.
Levallet G, Bergot E, Antoine M, Creveuil C, Santos AO, Beau-Faller M, de Fraipont F, Brambilla E, Levallet J, Morin F, Westeel V, Wislez M, Quoix E, Debieuvre D, Dubois F, Rouquette I, Pujol JL, Moro-Sibilot D, Camonis J, Zalcman G; on behalf of the Intergroupe Francophone de Cancérologie Thoracique (IFCT).
Mol Cancer Ther. 2012; 11 : 1203-1

Lung cancer in never smokers - A review.
Couraud S, Zalcman G, Milleron B, Morin F, Souquet PJ.
Eur J Cancer. 2012; 48 : 1299-311

Cost-effectiveness of three strategies for second-line erlotinib initiation in non small-cell lung cancer: the ERMETIC Study Part 3.
Borget I, Cadranel J, Pignon JP, Quoix E, Coudert B, Westeel V, Dansin E, Madelaine J, Madroszyk A, Friard S, Daniel C, Morin F, Chouaid C; the ERMETIC Collaborative Group.
Eur Respir J. 2012; 39 : 172-179

Chemotherapy in elderly patients with advanced non-small cell lung cancer.
Quoix E, Westeel V, Zalcman G, Milleron B.
Lung Cancer. 2011; 74 : 364-8

Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma
Hurbin A, Wislez M, Busser B, Antoine M, Tenaud C, Rabbe N, Dufort S, de Fraipont F, Moro-Sibilot D, Cadranel J, Coll JL, Brambilla E.
J Pathol. 2011 Sep;225(1):83-95

Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial.
Quoix E, Zalcman G, Oster JP, Westeel V, Pichon E, Lavolé A, Dauba J, Debieuvre D, Souquet PJ, Bigay-Game L, Dansin E, Poudenx M, Molinier O, Vaylet F, Moro-Sibilot D, Herman D, Bennouna J, Tredaniel J, Ducoloné A, Lebitasy MP, Baudrin L, Laporte S, Milleron B; Intergroupe Francophone de Cancérologie Thoracique.
Lancet 2011; 378 : 1079-88.

Cross-Validation Study for Epidermal Growth Factor Receptor and KRAS Mutation Detection in 74 Blinded Non-small Cell Lung Carcinoma Samples: A Total of 5550 Exons Sequenced by 15 Molecular French Laboratories (Evaluation of the EGFR Mutation Status for the Administration of EGFR-TKIs in Non-Small Cell Lung Carcinoma [ERMETIC] Project-Part 1).
Beau-Faller M, Degeorges A, Rolland E, Mounawar M, Antoine M, Poulot V, Mauguen A, Barbu V, Coulet F, Prétet JL, Bièche I, Blons H, Boyer JC, Buisine MP, de Fraipont F, Lizard S, Olschwang S, Saulnier P, Prunier-Mirebeau D, Richard N, Danel C, Brambilla E, Chouaid C, Zalcman G, Hainaut P, Michiels S, Cadranel J.
J Thorac Oncol. 2011; 6 : 1006-1015.

Non-small cell lung carcinoma: Perspectives for the twenty-first century?
Milleron B.
Presse Med. 2011; 40 : 368-370.

Metastatic non-small cell lung cancer: Systemic treatment of patients aged 70 and over.
Quoix E, Ducoloné A, Mennecier B, Fraisse P.
Presse Med. 2011; 40 : 420-426.

Prognostic and predictive biomarkers in non-small cell lung cancers. From conditioned registrations to routine molecular mapping of lung cancers: Methodological issues.
Bergot E, Levallet G, Creveuil C, Lechapt E, Zalcman G.
Presse Med. 2011; 40 : 379-388.

Pemetrexed re-challenge in pleural malignant mesothelioma: An option for a subset of patients initially treated with pemetrexed-platinum doublets in the first-line setting?
Zalcman G, Bergot E, Lechapt E.
Lung Cancer. 2011; 72 : 1-2.

A phase II study of cetuximab, pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non squamous, non-small cell lung cancer (NSCLC).
Tredaniel J, Mornex F, Barillot I, Diaz O, Hennequin C, Le Pechoux C, Lavole A, Giraud P, Souquet PJ, Teixeira L, Vaylet F, Zalcman G, Baudrin L, Morin F, Milleron B.
Rev Mal Respir. 2011; 28 : 51-57.

Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01).
Le Péchoux C, Laplanche A, Faivre-Finn C, Ciuleanu T, Wanders R, Lerouge D, Keus R, Hatton M, Videtic GM, Senan S, Wolfson A, Jones R, Arriagada R, Quoix E, Dunant A; on behalf of the Prophylactic Cranial Irradiation (PCI) Collaborative Group.
Ann Oncol. 2011; 22 : 1154-1163.

Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinib.
Wislez M, Antoine M, Baudrin L, Poulot V, Neuville A, Pradere M, Longchampt E, Isaac-Sibille S, Lebitasy MP, Cadranel J.
Lung Cancer  2010; 68 : 185-91

Update on nonsmall cell lung cancer.
Zalcman G, Bergot E, Lechapt E.
Eur Respir Rev. 2010 Sep;19(117):173-85

Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 or 3 (IFCT-0301 study).
Morère JF, Bréchot JM, Westeel V, Gounant V, Lebeau B, Vaylet F, Barlési F, Urban T, Souquet PJ, Debieuvre D, Baudrin L, Zalcman G, Morin F, Milleron B, Moro-Sibilot
Lung Cancer. 2010;  70 : 301-7.

Management and outcome of French elderly patients with lung cancer: an IFCT survey
Quoix E, Monnet I, Scheid P, Hamadouche A, Chouaid C, Massard G, Depierre A, Souquet PJ, Braun D, Girard P, Breton JL, Lebitasy MP, Milleron B; l'Intergroupe francophone de cancérologie thoracique (IFCT).
Rev Mal Respir  2010 May; 27 : 421-30.

The role of pemetrexed in lung adenocarcinoma, mixed subtype with bronchioloalveolar carcinoma features.
Duruisseaux M, Cadranel J, Pérol M, Arpin D.
Curr Drug Targets. 2010; 11 : 74-7.

Is neoadjuvant chemoradiotherapy a feasible strategy for stage IIIA-N2 non-small cell lung cancer? Mature results of the randomized IFCT-0101 phase II trial.
Girard N, Mornex F, Douillard JY, Bossard N, Quoix E, Beckendorf V, Grunenwald, Amour E, Milleron B.
Lung Cancer 2010; 69 : 86-93.

IFCT-0401 Trial: a phase II study of gefitinib administered as first-line treatment in advanced adenocarcinoma with bronchioloalveolar carcinoma subtype
Cadranel J, Quoix E, Baudrin L, Mourlanette P, Moro-Sibilot D, Morere JF, Souquet PJ, Soria JC, Morin F, Milleron B; IFCT-0401 Trial Group.
J Thorac Oncol 2009; 4 : 1126-35.

Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial.  
Le Péchoux C, Dunant A, Senan S, Wolfson A, Quoix E, Faivre-Finn C, Ciuleanu T, Arriagada R, Jones R, Wanders R, Lerouge D, Laplanche A; Prophylactic Cranial Irradiation (PCI) Collaborative Group.
Lancet Oncol. 2009; 10 : 435-7.

Patient participation in thoracic cancer clinical trials.
Pujol JL, Chakra M, Milleron B.
J Thorac Oncol. 2008 Jan;3(1):3-5.

How to treat the relapse of NSCLC after surgery and chemotherapy? IFTC 0702 randomized phase III study.
Moro-Sibilot D, Barlesi F, Timsit JF, Debieuvre D, Fournel P, Gervais R, Mazieres J, Milleron B, Morin F, Perol M, Soria JC, Souquet PJ, Vergnenègre A, Zalcman G.
Rev Mal Respir. 2008 Jan;25(1):91-6. French.

Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01.
Pujol JL, Breton JL, Gervais R, Tanguy ML, Quoix E, David P, Janicot H, Westeel V, Gameroff S, Geneve J, Maraninchi D.
J Clin Oncol. 2007 Sep 1;25(25):3945-51.

Complete response following preoperative chemotherapy for resectable non-small cell lung cancer: accuracy of clinical assessment using the French trial database.
Milleron B, Westeel V, Quoix E, Moro-Sibilot D, Braun D, Lebeau B, Depierre A; French Thoracic Cooperative Group.
Chest. 2005 Sep;128(3):1442-7

Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer.
Depierre A, Milleron B, Moro-Sibilot D, Chevret S, Quoix E, Lebeau B, Braun D, Breton JL, Lemarie E, Gouva S, Paillot N, Brechot JM, Janicot H, Lebas FX, Terrioux P, Clavier J, Foucher P, Monchatre M, Coetmeur D, Level MC, Leclerc P, Blanchon F, Rodier JM, Thiberville L, Villeneuve A, Westeel V, Chastang C; French Thoracic Cooperative Group.
J Clin Oncol. 2002 Jan 1;20(1):247-53.

IASLC Staging Article (IFCT and Participating Institutions)

The IASLC Lung Cancer Staging Project: Proposals for the Revision of the T Descriptors in the Forthcoming (Seventh) Edition of the TNM Classification for Lung Cancer.
Ramón Rami-Porta, MD; David Ball, MD, FRANZCR; John Crowley, PhD; Dorothy J. Giroux, MS; James Jett, MD; William D. Travis, MD; Masahiro Tsuboi, MD; Eric Vallières, MD; Peter Goldstraw, MB, FRCS; on behalf of the International Staging Committee; Cancer Research and Biostatistics; Observers to the Committee; Participating Institutions

The IASLC Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming Seventh Edition of the TNM Classification for Lung Cancer.
Valerie W. Rusch, MD; John Crowley, PhD; Dorothy J. Giroux, MS; Peter Goldstraw, MD; Jung-Gi Im, MD; Masahiro Tsuboi, MD; Ryosuke Tsuchiya, MD; Johan Vansteenkiste, MD; on behalf of the International Staging Committee; Cancer Research and Biostatistics; Observers to the Committee; Participating Institutions

The IASLC Lung Cancer Staging Project: Proposals for Revision of the M Descriptors in the Forthcoming (Seventh) Edition of the TNM Classification of Lung Cancer.
Pieter E. Postmus, MD, PhD; Elisabeth Brambilla, MD, PhD; Kari Chansky, MS; John Crowley, PhD; Peter Goldstraw, MB, FRCS; Edward F. Patz Jr, MD; Hiroyasu Yokomise, MD; on behalf of the International Association for the Study of Lung Cancer International Staging Committee,a Cancer Research and Biostatistics,b Observers to the Committee,c and Participating Institutions

The IASLC Lung Cancer Staging Project: Validation of the Proposals for Revision of the T, N, and M Descriptors and Consequent Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours.
Patti A. Groome, PhD; Vanessa Bolejack, MPH; John J. Crowley, PhD; Catherine Kennedy, RMRA; Mark Krasnik, MD; Leslie H. Sobin, MD; Peter Goldstraw, FRCS; on Behalf of the International Staging Committee, Cancer Research and Biostatistics, Observers to the Committee and Participating Institutions

The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours.
Peter Goldstraw, FRCS; John Crowley, PhD; Kari Chansky, MS; Dorothy J. Giroux, MSc; Patti A. Groome, PhD; Ramon Rami-Porta, MD; Pieter E. Postmus, PhD; Valerie Rusch, MD; Leslie Sobin, MD; on behalf of the International Association for the Study of Lung Cancer International Staging Committee and Participating Institutions

Article Revue des Maladies Respiratoires. 2007 Oct ; 24(8 Pt 2):6S120-4.
What treatment for a patient of PS 2-3 with stage IV non-small cell lung cancer?
Moro-Sibilot D, Pluquet E, Zalcman G, Bréchot JM, Souquet PJ, Debieuvre D, Morin F, Morère JF.

Standard, Options et Recommandations (SOR) pour le traitement périopératoire des patients atteints d'un cancer bronchique non à petites cellules résécable d'emblée, opérables (mise à jour), rapport abrégé
Oncologie (2007) 9: 800-809
B. Besse, A. Depierre, S. Guillo, C. Séblain-El Guerche, J-Y. Douillard, A. Giniès, C. Hennequin, C. Le Péchoux, B. Milleron, P. Mouillefarine, E. Quoix, D. Moro-Sibilot, J-F. Regnard, M. Riquet, F. Vaylet, G. Zalcman ; Fédération nationale des centres de lutte contre le cancer (FNCLCC) - Intergroupe Francophone de Cancerologie Thoracique (IFCT) - Société de pneumologie de langue française (SPLF).

Article Revue Maladies Respiratoires. 2007 May ; 24(5):645-52.
IFCT-0302 trial: Randomised study comparing two follow-up schedules in completely resected non-small cell lung cancer
Westeel V, Lebitasy MP, Mercier M, Girard P, Barlesi F, Blanchon F, Tredaniel J, Bonnette P, Woronoff-Lemsi MC, Breton JL, Azarian R, Falcoz PE, Friard S, Geriniere L, Laporte S, Lemarie E, Quoix E, Zalcman G, Guigay J, Morin F, Milleron B, Depierre A; Intergroupe Francophone de Cancerologie Thoracique (IFCT).

Westeel V.
Follow up of non small cell lung cancer. Should patients be followed up after surgery for non-small cell lung cancer and how?
Rev Mal Respir. 2006 Nov;23(5 Pt 3):16S84-16S87. Review.

Milleron B.
Rev Pneumol Clin. 2006 Dec;62(6 Pt 2):2S3.

Morin F.
[French clinical research in thoracic oncology.]
Rev Pneumol Clin. 2004 Nov;60(5 Pt 3):4S44-4S45.

Quoix E.
[IFCT --French Intergroup of Thoracic Cancerology: presentation, protocols]
Cancer Radiother. 2001 Jan-Feb;5(1):80-1.V

Lu 9790 fois Dernière modification le vendredi, 29 novembre 2019 11:11